The findings by Bhatt et al suggest enteric-coated aspirin
may be less effective at treating blood clots.
The FDA approval of YOSPRALA was based on the results from two randomised, double-blind controlled clinical trials that patients were randomly assigned to receive either YOSPRALA 325 mg/40 mg (n=524) or 325 mg of enteric-coated aspirin
Study participants were randomized to conventional enteric-coated aspirin
at 325 mg/day or to the investigational tablet, known for now as PA32540.
With repeated exposure, individuals categorized as nonresponders when given enteric-coated aspirin
showed evidence of responses when administered immediate-release aspirin.
Gastrointestinal blood loss with low dose (325 mg) plain and enteric-coated aspirin
is usually labeled "safety coated" or "safer on the stomach.
Although some trials have used enteric-coated aspirin
for initial dosing, more rapid buccal absorption occurs with non-enteric-coated formulations (AHA, 2004).
to prevent stroke after vertebral artery injury
Patients using enteric-coated aspirin
also were more likely than others to show resistance.
In a 2 1/2-year study of 517 people who had been cured of colorectal cancer, a new polyp was found in 17 percent of those taking a daily enteric-coated aspirin
(325 mg), compared to 27 percent of those taking a placebo.
The ADA recommends daily enteric-coated aspirin
for diabetic patients who already have evidence of cardiovascular disease and for those without CVD who have one or more risk factors for the disease, Ms.
(ECASA) is another very safe and much cheaper alternative to acetaminophen and much less expensive than the NSAIDs or the non-acetyl salicylates.
When enteric-coated aspirin
is involved, proper absorption may be delayed and the level of overdosage may not be apparent.
Subjects were randomly assigned to once-daily treatment with PA32540 or 325 mg of enteric-coated aspirin